Cero Therapeutics (CERO) CEO granted 4.53M stock options

Q: What insider transaction did CERO CEO Christopher B. Ehrlich report?

Christopher B. Ehrlich, Chairman and CEO of Cero Therapeutics Holdings, Inc. (CERO) , reported receiving a stock option grant for 4,530,997 shares of common stock.

Q: When were the new CERO stock options granted and when do they expire?

The stock option was granted on January 7, 2026 and is listed with an expiration date of January 6, 2036 .

Q: Is the new CERO stock option grant to the CEO held directly or indirectly?

The Form 4 indicates the ownership form is Direct (D) , meaning the stock option grant is held directly by Christopher B. Ehrlich.

Q: Did Christopher B. Ehrlich pay anything for the CERO stock options themselves?

The filing shows a price of $0.00 for the derivative security, indicating no cash price was paid to receive the stock option grant, while the exercise price is $0.055 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Cero Therapeutics Holdings, Inc. reported that Chairman and CEO Christopher B. Ehrlich received a large stock option grant. On January 7, 2026, he was awarded a stock option to buy 4,530,997 shares of common stock at an exercise price of $0.055 per share. The option is exercisable from January 7, 2026 and expires on January 6, 2036. Following this grant, he beneficially owns 4,530,997 derivative securities, held as a direct ownership position, and there was no cash price paid for the option itself.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ehrlich Christopher B

Role Chairman and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	4,530,997	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 4,530,997 shares (Direct)

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/09/2026 - 04:30 PM

FAQ

What insider transaction did CERO CEO Christopher B. Ehrlich report?

Christopher B. Ehrlich, Chairman and CEO of Cero Therapeutics Holdings, Inc. (CERO), reported receiving a stock option grant for 4,530,997 shares of common stock.

What is the exercise price of the new CERO stock options granted to the CEO?

The stock option granted to Christopher B. Ehrlich has an exercise price of $0.055 per share for the underlying common stock of Cero Therapeutics Holdings, Inc.

When were the new CERO stock options granted and when do they expire?

The stock option was granted on January 7, 2026 and is listed with an expiration date of January 6, 2036.

How many derivative securities does the CERO CEO own after this transaction?

After this transaction, Christopher B. Ehrlich beneficially owns 4,530,997 derivative securities (stock options) related to Cero Therapeutics common stock.

Is the new CERO stock option grant to the CEO held directly or indirectly?

The Form 4 indicates the ownership form is Direct (D), meaning the stock option grant is held directly by Christopher B. Ehrlich.

Did Christopher B. Ehrlich pay anything for the CERO stock options themselves?

The filing shows a price of $0.00 for the derivative security, indicating no cash price was paid to receive the stock option grant, while the exercise price is $0.055 per share.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ehrlich Christopher B

(Last)

(First)

(Middle)

CERO THERAPEUTICS HOLDINGS, INC.

201 HASKINS WAY, SUITE 230

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CERO THERAPEUTICS HOLDINGS, INC. [ CERO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairman and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.055	01/07/2026		A		4,530,997		01/07/2026	01/06/2036	Common Stock	4,530,997	$0.00	4,530,997	D

Explanation of Responses:

	/s/ Andrew Kucharchuk, Attorney-in-Fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR